H.C. Wainwright lowered the firm’s price target on AnaptysBio (ANAB) to $52 from $59 and keeps a Buy rating on the shares after the Phase 2 rosnilimab trial in ulcerative colitis does not meet the primary endpoint. The firm removed ulcerative colitis revenues from its model.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB: